Nymox is alleging that AscellaHealth—which Nymox refers to as “a would-be ‘black knight’ competitor”—resorted to “illegal and unlawful corporate espionage” because it couldn’t gain enough support from Nymox shareholders by “legitimate means.”
Nymox is accusing Ascella of using its ties to the ex-Nymox leaders to pass off an investment proposal as a way to learn confidential company information and take control of the company's assets via a kick-back scheme, according to the biotech’s Nov. 9 release. more
